NZ608721A - Crystalline oxalate salts of a diamide compound - Google Patents
Crystalline oxalate salts of a diamide compoundInfo
- Publication number
- NZ608721A NZ608721A NZ60872111A NZ60872111A NZ608721A NZ 608721 A NZ608721 A NZ 608721A NZ 60872111 A NZ60872111 A NZ 60872111A NZ 60872111 A NZ60872111 A NZ 60872111A NZ 608721 A NZ608721 A NZ 608721A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline oxalate
- salt
- oxalate salts
- crystalline
- diamide compound
- Prior art date
Links
- 150000003891 oxalate salts Chemical class 0.000 title abstract 5
- -1 diamide compound Chemical class 0.000 title 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 208000019693 Lung disease Diseases 0.000 abstract 1
- AKYUMGLGSXQSCR-FAIXQHPJSA-N [1-[3-[[5-[4-[[[(2r)-2-hydroxy-2-(8-hydroxy-2-oxo-1h-quinolin-5-yl)ethyl]amino]methyl]anilino]-5-oxopentyl]-methylamino]-3-oxopropyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical class C=1C=C(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)C=CC=1NC(=O)CCCCN(C)C(=O)CCN(CC1)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 AKYUMGLGSXQSCR-FAIXQHPJSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38814810P | 2010-09-30 | 2010-09-30 | |
| PCT/US2011/053997 WO2012044825A1 (en) | 2010-09-30 | 2011-09-29 | Crystalline oxalate salts of a diamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ608721A true NZ608721A (en) | 2015-03-27 |
Family
ID=44903347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60872111A NZ608721A (en) | 2010-09-30 | 2011-09-29 | Crystalline oxalate salts of a diamide compound |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8697724B2 (https=) |
| EP (1) | EP2621917A1 (https=) |
| JP (2) | JP2013538857A (https=) |
| KR (1) | KR20130139919A (https=) |
| CN (1) | CN103140485B (https=) |
| AR (1) | AR083115A1 (https=) |
| AU (1) | AU2011308770B2 (https=) |
| BR (1) | BR112013007062A2 (https=) |
| CA (1) | CA2810896A1 (https=) |
| CL (1) | CL2013000870A1 (https=) |
| CO (1) | CO6700846A2 (https=) |
| EA (1) | EA022018B1 (https=) |
| IL (1) | IL224985A (https=) |
| MX (1) | MX2013003558A (https=) |
| NZ (1) | NZ608721A (https=) |
| PH (1) | PH12013500567A1 (https=) |
| SG (1) | SG188390A1 (https=) |
| TW (1) | TW201217338A (https=) |
| WO (1) | WO2012044825A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| CN104030933A (zh) * | 2014-05-16 | 2014-09-10 | 烟台恒迪克能源科技有限公司 | 一种β-异烷醇基氨基戊酸环己胺的合成方法 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| CN117924216A (zh) * | 2024-01-12 | 2024-04-26 | 王叔和生物医药(武汉)有限公司 | 一种1-哌啶丙酸的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1775305T1 (sl) | 2000-08-05 | 2015-01-30 | Glaxo Group Limited | S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| JP4767842B2 (ja) * | 2003-04-01 | 2011-09-07 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
| WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| TW200811104A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| MX2011011156A (es) | 2009-04-23 | 2011-11-04 | Theravance Inc | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. |
-
2011
- 2011-09-26 AR ARP110103518A patent/AR083115A1/es unknown
- 2011-09-29 SG SG2013016043A patent/SG188390A1/en unknown
- 2011-09-29 EA EA201390481A patent/EA022018B1/ru not_active IP Right Cessation
- 2011-09-29 WO PCT/US2011/053997 patent/WO2012044825A1/en not_active Ceased
- 2011-09-29 JP JP2013531861A patent/JP2013538857A/ja not_active Ceased
- 2011-09-29 AU AU2011308770A patent/AU2011308770B2/en not_active Ceased
- 2011-09-29 EP EP11771325.5A patent/EP2621917A1/en not_active Withdrawn
- 2011-09-29 CA CA2810896A patent/CA2810896A1/en not_active Abandoned
- 2011-09-29 US US13/248,840 patent/US8697724B2/en not_active Expired - Fee Related
- 2011-09-29 CN CN201180046585.5A patent/CN103140485B/zh not_active Expired - Fee Related
- 2011-09-29 KR KR1020137009556A patent/KR20130139919A/ko not_active Withdrawn
- 2011-09-29 BR BR112013007062A patent/BR112013007062A2/pt not_active IP Right Cessation
- 2011-09-29 PH PH1/2013/500567A patent/PH12013500567A1/en unknown
- 2011-09-29 NZ NZ60872111A patent/NZ608721A/en not_active IP Right Cessation
- 2011-09-29 MX MX2013003558A patent/MX2013003558A/es not_active Application Discontinuation
- 2011-09-30 TW TW100135675A patent/TW201217338A/zh unknown
-
2013
- 2013-02-28 IL IL224985A patent/IL224985A/en not_active IP Right Cessation
- 2013-03-28 CL CL2013000870A patent/CL2013000870A1/es unknown
- 2013-04-02 CO CO13061812A patent/CO6700846A2/es active IP Right Grant
-
2015
- 2015-06-01 JP JP2015111163A patent/JP2015155470A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013538857A (ja) | 2013-10-17 |
| AU2011308770A1 (en) | 2013-03-28 |
| EA201390481A1 (ru) | 2013-08-30 |
| AU2011308770B2 (en) | 2015-03-05 |
| JP2015155470A (ja) | 2015-08-27 |
| CN103140485B (zh) | 2014-10-22 |
| CO6700846A2 (es) | 2013-06-28 |
| US20120083478A1 (en) | 2012-04-05 |
| SG188390A1 (en) | 2013-04-30 |
| WO2012044825A1 (en) | 2012-04-05 |
| US8697724B2 (en) | 2014-04-15 |
| CL2013000870A1 (es) | 2013-07-12 |
| CA2810896A1 (en) | 2012-04-05 |
| CN103140485A (zh) | 2013-06-05 |
| IL224985A (en) | 2015-08-31 |
| AR083115A1 (es) | 2013-01-30 |
| EA022018B1 (ru) | 2015-10-30 |
| PH12013500567A1 (en) | 2013-05-06 |
| EP2621917A1 (en) | 2013-08-07 |
| KR20130139919A (ko) | 2013-12-23 |
| TW201217338A (en) | 2012-05-01 |
| MX2013003558A (es) | 2013-05-01 |
| BR112013007062A2 (pt) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ608721A (en) | Crystalline oxalate salts of a diamide compound | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| NZ734896A (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| MX2013011551A (es) | Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales. | |
| NZ599587A (en) | Method for producing dabigatran etexilate | |
| IN2014CN00712A (https=) | ||
| MY150778A (en) | Fused heterocyclic compound | |
| TW200714586A (en) | Crystalline forms of a biphenyl compound | |
| TW200800948A (en) | Novel compound | |
| EA201491079A1 (ru) | Арил дигидропиридиноновые и пиперидиноновые ингибиторы mgat2 | |
| WO2019132561A8 (ko) | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 | |
| HK1206021A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| MX2016001096A (es) | Sales de dasatinib en forma amorfa. | |
| CO6710915A2 (es) | Composiciones farmacéuticas que contienen un inhibidor de dgat1 ácido 4-(4-(5-6(- trifluorometil-piridin -3- ilamino)-piridin- 2-il)fenil)cicloheiyl)-acético o sales del mismo | |
| NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
| MY159870A (en) | Piperazine compound capable of inhibiting prostaglandin d synthase | |
| WO2014102592A3 (en) | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof | |
| CA2899024C (en) | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid | |
| MX2016001095A (es) | Sales de dasatinib en forma cristalina. | |
| FI3909956T3 (fi) | Heterosyklisen johdannaisyhdisteen hydrokloridisuola-1,5-hydraatti | |
| WO2015044853A3 (en) | Process for preparation of dimethyl fumarate | |
| WO2014195593A3 (fr) | Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant | |
| WO2014049586A3 (en) | Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof | |
| IL206570A (en) | 4,3-Dihydro Compound-1 h- Isoquinoline is converted into 3 positions, process for preparation and use | |
| PL2234974T3 (pl) | Sposób otrzymywania związku (s)-1-alkilo-2', 6'-pipekoloksylidydu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: THERAVANCE RESPIRATORY COMPANY, US Effective date: 20140807 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 SEP 2016 BY COMPUTER PACKAGES INC Effective date: 20150901 |
|
| LAPS | Patent lapsed |